Diana Widicus
Family Medicine · Rochester, ILNPI 1851471072
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $814 and has fallen 57.0% since, to $350 in 2021.
Across 105 payments — averaging $16.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$395
- Lilly USA, LLC$127
- AMAG Pharmaceuticals, Inc.$112
- Abbott$109
- Boehringer Ingelheim$109
- Astellas Pharma US Inc$108
- plus $737 from 23 others
Across 371 payments — averaging $7190.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2.4M
- Regeneron$128K
- Novo Nordisk AS$107K
- Lexicon Pharmaceuticals, Inc.$31K
What the payments were for
- Food & beverage$1,691100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $395 |
| Lilly USA, LLC | 9 | $127 |
| AMAG Pharmaceuticals, Inc. | 1 | $112 |
| Abbott | 8 | $109 |
| Boehringer Ingelheim | 8 | $109 |
| Astellas Pharma US Inc | 7 | $108 |
| Esperion Therapeutics, Inc. | 7 | $99 |
| Novo Nordisk | 6 | $85 |
| Pfizer | 6 | $77 |
| Eisai Inc. | 4 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $48 |
| Sanofi-aventis U.S. LLC | 3 | $39 |
| Amgen | 2 | $33 |
| AbbVie | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Johnson & Johnson | 2 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $19 |
| GSK | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $17 |
| Nabriva Therapeutics, PLC | 1 | $17 |
| Circassia Inc. | 1 | $16 |
| Biodelivery Sciences International, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Novartis | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FERAHEME$112
How this compares
$1,697 in reported general payments places this provider in the 80th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Rochester
- Frank PhillipsChicago$1.6M
- Peter TothSterling$1.4M
- Bradley TorphyChicago$1.3M
- Jeffrey RoyceRockford$890K
- Anthony AuriemmaWestmont$788K
- Manfred ManGurnee$764K
- Barbara BellarOakbrook Terrace$599K
- Bernie RancheroAltamont$533K
- Sandy GibsonChicago$309K
- Mandy GittlerChicago$204K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.